BACKGROUND: Metabolic adaptation and maladaptation are hallmarks of the failing heart and may be a target for therapeutic ...
Proteins regulate a wide range of biological processes inside and outside cells by binding to specific molecular partners. In ...
Clinical Trials Arena on MSN
FDA clears Atrium’s IND application to begin Corventis trial of ATR 1072
Atrium Therapeutics expects to enrol the first participant by the end of 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results